SLC5A2 and type 1 diabetes mellitus: T1D and T2D may share metabolic, inflammatory, and hemodynamic mechanisms, and we speculated that treatment with an SGLT2 inhibitor may provide additional non-glycemic benefits to individuals with T1D as they have in those with T2D.